BENCHMARKS LIVE
FEATURED FUNDS
Sensex 72,822.91
114.75
★★★★★
3Y RETURN
Canara Robeco Small C…
31.15 %
Search Stock Quotes, News, Mutual Funds and more
INVEST NOW
Industry
English Edition
Home
Auto
ETPrime
Markets
Banking/Finance
News
Industry
Cons. Products
Rise
Energy
Politics
Wealth
Renewables
PRIME MEMBER
SWATI
| Today's ePaper
Mutual Funds
Ind'l Goods/Svs
Tech
Careers
Opinion
Healthcare/Biotech
NRI
Services
Panache
•
•
Spotlight
Media/Entertainment
More
Business News › Industry › Healthcare/Biotech › Healthcare › Beta Blockers – A discovery that transformed cardiac disease management!
The Economic Times daily newspaper is available online now.
Read Today's Paper
ADVERTORIAL
Beta Blockers – A discovery that transformed
cardiac disease management!
1
Beta Blockers
– A2023,
discovery
that
transformed
cardiac disease management!
Spotlight
SECTIONS
Wire Last Updated:
Jun 13,
07:22:00
PM
IST
FOLLOW US SHARE
FONT SIZE SAVE PRINT COMMENT
Synopsis
The advent of selective beta-blockers has transformed cardiovascular medicine by
providing clinicians with a range of tailored treatment options. Read to know more
Cardiovascular diseases (CVDs), one of
the world's leading causes of death,
claim as many as 17.9 million lives each
year globally. According to a study by
the Indian Council of Medical Research
and Registrar General of India, India
accounts for approximately 60% of the
global burden of heart disease.
Additionally, the study highlights a
high prevalence of hypertension in the country, with as much as 30% of the
population aYected. Notably, 62.5% of newly diagnosed hypertensive
individuals have high sympathetic overactivity. The study further found that
there is a signi]cant lack of awareness, treatment, and control of high blood
pressure among young adults with hypertension.
Spotlight Wire
Amongst the armamentarium of drugs for the management of cardiac disease,
the advent of selective beta-blockers has transformed cardiovascular medicine
by providing clinicians with a range of tailored treatment options. These
medications have revolutionised the management of hypertension, angina,
and heart failure by speci]cally targeting beta-1 receptors while minimising
adverse eYects on other physiological systems.
Spotlight Wire
The journey of beta-blocker development began in the mid-20th century when
scientists delved into understanding the role of the sympathetic nervous
system in cardiovascular function. A signi]cant milestone in beta-blocker
development occurred in the 1950s when James W. Black and his colleagues
focused on receptor pharmacology, aiming to identify compounds that could
alone block the beta-adrenergic receptor subtype. In the early 1960s, Black and
his team developed a molecule called propranolol, which later paved the way
for more cardio (beta-1 receptors in the heart)-selective and convenient betablockers like bisoprolol.
Spotlight Wire
Bisoprolol, for instance, has gained the trust of patients worldwide for over 3
decades. It is widely utilised as a reliable and well-established medication in
the management of various conditions. Its selectivity for beta-1 receptors
made it a favourable choice in patients with concomitant respiratory
conditions.
The most prominent question that arises in our mind is how beta-blockers
work. These medications exert their eYects by blocking the release of stress
hormones, such as adrenaline and noradrenaline, in speci]c areas of the body.
As a result, they slow down the heart rate and decrease the force with which
blood is pumped throughout the body. Additionally, beta blockers can inhibit
the production of a hormone called angiotensin II by the kidneys,
contributing to the signi]cant lowering of blood pressure.
Researchers and cardiologists have found strong evidence that taking a beta
blocker after a heart attack decreases the chances of early death by 44%.
Beta-blockers are also known to improve long-term outcomes in heart failure,
blood pressure control and coronary diseases. Beta-blockers have been
extensively used globally, and the cardio-selective ones are known to be well
tolerated in most patients, leading to high compliance among patients.
✕
MORE STORIES FOR YOU
Ka-Ching: How global drug makers are riding on luck in
their pursuit of blockbuster drugs, vaccines
FEB 15, 2024
Business and valuation tailwinds to help in
outperformance? 5 Indian pharma stocks with upside
potential of up to 32%
FEB 18, 2024
Netcix March 2024 Departures Line-up: Check out
complete list
FEB 10, 2024
Therefore, we, at Merck, on this day, pay our tributes to Sir James Whyte Black
for the novel discovery of Beta-blockers on his 99th birth anniversary. (14 June
1924 – 22 March 2010).
Here is what the doctors have to say:
Spotlight Wire
Dr Jamshed J Dalal, Mumbai, said, “Beta blockers are important drugs in the
management of the whole spectrum of cardiovascular disease. They are used
in the treatment of hypertension, heart failure, coronary artery disease,
cardiomyopathies and arrhythmias. Indians have a higher heart rate than
Westerners, and beta blockers help stabilise it. They not only relieve symptoms
but often improve survival. They are also used for tremors, migraine and
glaucoma. They have been extensively used in India for many decades and
helped millions of people. For this, we owe gratitude to Sir James Black, who
developed this molecule.”
Dr J C Mohan, Delhi, said, “Bisoprolol represents the best-in-class beta
blocker with strong evidence and least side eYects. Its ease of use, compliance,
and adherence are remarkable.”
Dr Arup Dasbiswas, Kolkata, said, “India is the world capital of
cardiovascular disease (CVD), and CVD is the leading cause of death. Betablockers, particularly highly cardio-selective beta blockers like bisoprolol, are
very useful drugs, reducing the eYects of sympathetic hyperactivity. Betablockers are a class of medications that block the eYects of adrenaline and
related stress hormones. They are commonly prescribed to treat high blood
pressure, fast heart rates, heart rhythm disorders, angina, and heart failure.
After a heart attack, they decrease mortality and further events. Bisoprolol has
more good eYects and less of side eYects.”
Dr Jayagopal P B, Palakkad, said, “One of the biggest breakthroughs in the
therapy of angina, hypertension, and cardiovascular disease, has been the
advent of beta-blockers in the market. Undoubtedly, beta-blocker therapy has
been a blessing for patients with angina. Following heart attacks, the eYicacy
is well established. This is one of the guideline-directed medical therapy for
reducing death and hospital admissions. Bisoprolol, introduced as the betablocker of choice in smokers, is indeed a very eYective agent. Its long duration
of action and safety in patients with diabetes, dyslipidemia and kidney
disease makes it one of the most desirable agents. This is my preferred betablocker in cardiac patients.”
Disclaimer: The views and opinions eDpressed in the story are
independent professional judgement of the eDperts and we do not take
any responsibility for the accuracy of their views. This should not be
considered as a substitute for medical advice. Please consult your treating
physician for more details. The above is non-editorial content and ET does
not guarantee, vouch or endorse any of the above content, nor is it
responsible for them in any manner whatsoever. Please take all steps
necessary to ascertain that any information and content provided is
correct, updated, and veriIed.
(You can now subscribe to our Economic Times JhatsApp channel)
VIEW 1 COMMENTS ON THIS STORY
READ MORE NEWS ON
Betablockers
Cardiovasculardiseases
Functioningofbetablockers
SirJamesWhyteBlack
Hypertensionrelief
(Catch all the Business News, Breaking News Budget 2024 News, Budget...more
2024 Live Coverage, Events and Latest News U
Download The Economic Times News App to get Daily Market Updates & Live Business News.
NEXT STORY
HCG stake sale: A big acquisition deal likely
coming up for HCG as EQT, TPG and KKR eye
majority stake
By Arijit Barman & Viswanath Pilla, ET Bureau
Last Updated: Feb 19, 2024, 12:17:00 PM IST
FOLLOW US SHARE
FONT SIZE SAVE PRINT COMMENT
Synopsis
A rising middle-class and an aging population have boosted demand for private medical
services across Asia, which in turn, is seeing massive consolidation and heightened deal
activity in the healthcare sector.
Agencies
Representative Image
Mumbai: Global buyout funds EQT
(formerly Baring PE Asia-EQT), TPG
Capital and KKR are among those
evaluating the acquisition of a
controlling stake held by CVC Capital
in Bengaluru-based specialty cancer
hospital chain Healthcare Global
Enterprises (HCG), sources told ET.
A rising middle-class and an aging population have boosted demand for
private medical services across Asia, which in turn, is seeing massive
consolidation and heightened deal activity in the healthcare sector.
Luxembourg-based CVC manages 188 billion of assets and is also owner of
the Gujarat Titans’ IPL franchise, international rugby union, Women’s Tennis
Association and top football properties such as Spain's La Liga or consumer
brands like Lipton Teas, Peruvian cash management company Hermes, among
others. It owns around 60.41% stake in HCG.
BS Ajai Kumar, an oncologist-turned-entrepreneur and founder of HCG, and
his family members own about 11% stake in the company.
The US PE fund bought a controlling stake in HCG in June 2020 for about Rs
1,049 crore by buying new shares and convertible warrants. It acquired more
shares later through a mandatory open oYer.
✕
MORE STORIES FOR YOU
Fundamental Radar: Three factors to drive 15% sales
CAGR for Apollo Hospitals, says Sneha Poddar
FEB 20, 2024
Stressed return ratios a drag on Rashi Peripherals
FEB 05, 2024
Dr BS Ajaikumar on CVC selling Healthcare Global
controlling stake, future plans and more
FEB 19, 2024
As on February 18, CVC stake in HCG would be worth around Rs 3,236 crore.
The deal would involve an open oYer for an additional 26% of the company.
The current market value of the hospital chain is Rs 5,357.38 crore. A recent
report by brokerage ]rm JeYeries also highlighted that CVC’s investment in
the cancer hospital chain has increased 2.7 times in less than three years.
In the past one month, the HCG stock is up 10% as the sale gathers
momentum.
CVC Capital is working with two Wall Street advisors for the sale that has
been launched in recent weeks. The oYicial sale process was launched
recently.
Ajai Kumar told ET that he is not looking to sell his stake and exit.
“There is no intention to exit. I have founded and built HCG, and am
committed to the cause of serving cancer patients,” said Ajai Kumar, executive
chairman of HCG.
EQT declined to comment. CVC, TPG and KKR were not available for
comment.
Both these funds are involved in the biggest hospital deals involving private
equity (PE) investors in India. While KKR had one of its big pay days exiting
Max Healthcare in what was the largest block deal in the Indian stock
market history, TPG has backed several hospital chains but its largest bet has
been Manipal. Last year, TPG, an investor in Manipal since 2015, chose to fully
exit Ranjan Pai’s hospital chain by selling its stake to Temasek, but it also
decided to reinvest in Manipal via a new fund, albeit with a smaller holding.
Even EQT that has traditionally been overweight on tech and BPO deals has
been doubling down on healthcare. In 2022, EQT bought Hyderabadheadquartered super specialty hospital AIG (Asian Institute of
Gastroenterology), pipping TPG. Last September, it acquired 60-65% of Indira
IVF for $650-700 million, the largest provider of fertility services in India and
also among the top ]ve globally in terms of annual in-vitro fertilisation (IVF)
cycles, for a billion-dollar valuation, in a headline-grabbing deal.
HCG has 1,926 operational beds, of which nearly three-fourths belong to
matured hospitals and the rest from the new ones. The company is spending
Rs 132 crore on capex on two hospitals — Ahmedabad (Rs 106 crore) and
White]eld, Bengaluru (Rs 25 crore).
Founded in 2005, HCG now operates 22 cancer hospitals and three
multispecialty hospitals across India. The network also includes one cancer
care centre in Kenya.
The debt-fuelled expansion and Covid-19 pandemic that disrupted cancer care
services have massively dented the company's ]nancial performance,
particularly in FY21.
Cancer care infrastructure, especially facilities to oYer radiation therapy, are
expensive.
The timely equity infusion by CVC and the appointment of Raj Gore as CEO in
February 2021, who prioritised operational eYiciency, cost optimisation and
rationalisation of bed capacities, have helped HCG to get back in the pink of
health.
Operating ProIt, Revenue
HCG revenues grew 13% year-on-year (YoY) in the nine months ended
December 31 to Rs 1,417.5 crore. It has an earnings before interest, tax,
depreciation and amortisation (ebitda) margin of 17.3% in the same period.
The company said it is striving to achieve 20% ebitda margin and revenue
growth above the market growth rate of 10-11%. The net debt stood at Rs 367
crore as on December 2023.
The consolidated revenue grew by 21% during FY23 on the back of increased
admissions and procedures performed. The momentum was sustained in
H1FY24, with the company reporting growth of 14.5% on Yo-Y basis.
While in absolute terms, the pro]t before depreciation, interest and tax
(PBDIT) of the company grew but PBDIT margins improved marginally from
17.06% in FY22 to 17.60% in FY23 as increasing share of low-margin medical
oncology and continuing losses in some of the new centres like south Mumbai
and Kolkata limited margin gains. Nevertheless, these new centres have been
witnessing increasing footfalls and are likely to turnaround in the near term.
HCGEL is ]rmly placed to tap the increasing demand for cancer treatment,
which would continue to drive the revenue growth, said CARE Ratings in a
recent credit note.
HCG has also been looking to acquire cancer hospitals. In FY24 alone, HCG
announced acquisitions of 120-bed Nagpur Cancer Hospital and Research
Institute and 100-bed SRJ CBCC Cancer Hospital in Indore, giving the
hospital chain a ]rm footing in central India and south India.
Analysts believe its dominant presence in cancer care treatment is driven by
strong brand equity and superior quality of service along with partnership
with other established medical professionals. The company also operates
seven IVF fertility centres under the brand ‘Milann’ through its wholly owned
subsidiary, BACC Healthcare Private Limited (BACC).
EQT may subsequently explore merging it with Indira if it emerges as the
successful bidder.
(You can now subscribe to our Economic Times JhatsApp channel)
READ MORE NEWS ON
Eqt
Kkr
HCG
CVC Capital
TPG Capital
Block Deal
Stock Market
Bengaluru
Specialty Cancer Hospital
(Catch all the Business News, Breaking News Budget 2024 News, Budget...more
2024 Live Coverage, Events and Latest News U
Download The Economic Times News App to get Daily Market Updates & Live Business News.
Search News, Stock Quotes & NAV
Trending Now
Maruti Suzuki Ertiga
RBI MPC Meet Live
Budget 2024 Highlights
Budget 2024 Real Estate
Railways Budget 2024
India auto sales september
MORE
Hot On Web
Sensex Today
Suhani Bhatnagar Death
Bharat Bandh Live
CTET Result
PM Modi UAE Visit
EPFO Interest Rate Hike
MORE
In Case You Missed It
Maruti Suzuki Ertiga
RBI MPC Meet Live
India Budget Highlights 2024
Budget 2024 Real Estate
Railways Budget 2024
India auto sales
MORE
Statistics Calculator
MORE
Top Calculators
Standard Deviation Calculator
Income Tax Calculator
Age Calculator
Time Calculator
BMI Calculator
GPA Calculator
Top Searched Companies
IDFC Share Price
Bank of Baroda Share Price
Titan Company Share Price
Hindalco Share Price
Bajaj Finance Share Price
MORE
Top Prime Articles
3 Insights To Kick Start Your Day…
Hirakud Industrial Works Insolve…
After Dodging Bankruptcy Thric…
4 Insights To Kick Start Your Day…
MORE
Top Story Listing
Epf
Netflix News
Cognizant Layoffs
Instagram Down
Narendra Modi
MORE
Top Slideshow
Youve Been Doing It Wrong
Hg Infra Engineering
Itc
Income Tax Rule Change Salarie…
Youve Been Doing It Wrong
Itc
MORE
Top Videos
Air Indias Mega 80 Billion Deal …
Adani Enterprises Adani Ports A…
Chatgpt Vs Bard Google Micros…
Adani Groups Cfo Jugeshinder S…
MORE
Top Definitions
Monetary Policy
Advertising
Commercial Bank
Perfect Competition
Non Performing Assets
MORE
Most Searched IFSC Codes
Indian Bank
Union Bank Of India
Punjab National Bank
State Bank Of India
Bank Of Baroda
MORE
Private Companies
Campa Cola Co Pvt Ltd
Excellent Escort Services Private…
Vihaan Direct Selling India Priva…
Awpl Ayurveda Private Limited
MORE
Other Useful Links
About Us
Archive
Follow Us On:
Terms of Use & Grievance Redressal
Economic Times ePaper
Privacy policy
Create Your Own Ad
Advertise with Us
MORE
Download ET App:
subscribe to our newsletter
Copyright © 2024 Bennett, Coleman & Co. Ltd. All rights reserved. For reprint rights: Times Syndication Service
BACK TO TOP